Head to Head Comparison: Lifeward (NASDAQ:LFWD) and Femasys (NASDAQ:FEMY)

Lifeward (NASDAQ:LFWDGet Free Report) and Femasys (NASDAQ:FEMYGet Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Lifeward and Femasys’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lifeward -141.28% -235.86% -81.72%
Femasys -534.36% -225.97% -74.68%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lifeward and Femasys, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward 1 1 2 0 2.25
Femasys 1 0 3 0 2.50

Lifeward presently has a consensus target price of $10.00, suggesting a potential upside of 41.34%. Femasys has a consensus target price of $50.00, suggesting a potential upside of 1,591.47%. Given Femasys’ stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Lifeward.

Risk and Volatility

Lifeward has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.07, meaning that its stock price is 307% less volatile than the S&P 500.

Institutional & Insider Ownership

26.8% of Lifeward shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 1.5% of Lifeward shares are held by company insiders. Comparatively, 7.7% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lifeward and Femasys”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lifeward $22.03 million 0.91 -$19.91 million ($16.82) -0.42
Femasys $2.29 million 10.82 -$18.63 million ($3.53) -0.84

Femasys has lower revenue, but higher earnings than Lifeward. Femasys is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Summary

Femasys beats Lifeward on 10 of the 14 factors compared between the two stocks.

About Lifeward

(Get Free Report)

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Femasys

(Get Free Report)

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Receive News & Ratings for Lifeward Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeward and related companies with MarketBeat.com's FREE daily email newsletter.